D-0059-2023 Class III Terminated

Recalled by Aadi Bioscience — Pacific Palisades, CA

FDA drug recall D-0059-2023 was initiated by Aadi Bioscience on October 13, 2022 and is designated Class III. Reason for recall: Failed Stability Specifications The recall status is terminated (terminated March 16, 2023). Affected quantity: 2,333 vials.

Recall Details

Product Type
Drugs
Report Date
November 23, 2022
Initiation Date
October 13, 2022
Termination Date
March 16, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,333 vials

Product Description

Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.

Reason for Recall

Failed Stability Specifications

Distribution Pattern

Within the U.S Market - PA, AL, KY, TN

Code Information

Lot# 6025701, Expiration Date: 31MAR2023, 100mg/vial, 50 ml single use vial, NDC 80803-153-50.